Skip to main content

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

A federal judge has banned the sale of Regeneron Pharmaceuticals' (REGN) cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen (AMGN)  and its competing drug Repatha in a long-running patent lawsuit. Regeneron and Sanofi (SNY) intend to appeal both the original patent infringement decision and the judge's injunction against Praluent.

This article was written by a staff member of TheStreet.